Top Markets
Coin of the day
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Rangering i aksjer #31255
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Aksjekurs
$0.39
Markedsverdi
$13.79M
Endring (1 dag)
-13.53%
Endring (1 år)
-68.80%
Land
IL
Handel NeuroSense Therapeutics Ltd. (NRSN)

Kategori

EPS for NeuroSense Therapeutics Ltd. (NRSN)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til NeuroSense Therapeutics Ltd. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for NeuroSense Therapeutics Ltd. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$13.70 -
BE